Get the latest news, insights, and market updates on ZLAB (Zai Lab Limited). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
SHANGHAI & CAMBRIDGE, Mass., September 02, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Sep 2, 2025 - $ZLAB
Zai Lab Announces Participation in Investor Conferences in September 2025
SHANGHAI & CAMBRIDGE, Mass., August 28, 2025--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in September 2025: Aug 28, 2025 - $ZLAB
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.